TY  - JOUR
AU  - Gambichler, Thilo
AU  - Iordanou, Maria
AU  - Becker, Jürgen C
AU  - Susok, Laura
TI  - Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.
JO  - Melanoma research
VL  - 34
IS  - 1
SN  - 0960-8931
CY  - [Erscheinungsort nicht ermittelbar]
PB  - Ovid
M1  - DKFZ-2023-02270
SP  - 80-83
PY  - 2024
N1  - 2024 Feb 1;34(1):80-83 / Short communication
AB  - Intratumoural as well as systemic inflammation in melanoma has thoroughly been studied in the context of patients treated with immune checkpoint inhibitors but not with BRAF/MEK inhibitors (BRAFi/MEKi). We aimed to study whether parameters of intratumoral and systemic inflammation correlate with clinical outcome in patients with BRAF-mutant metastatic melanoma treated with BRAFi/MEKi. We studied 51 CM patients with unresectable stage III or IV who had the indication for BRAFi/MEKi treatment based on confirmed BRAF mutation. Baseline systemic immune-inflammation markers such as the systemic immune-inflammation index (SII) and the expression of intratumoral inflammation markers such as COX-2 protein expression were correlated with clinical outcome measures. On multivariable analyses, lower intratumoral COX-2 expression (OR 33.9, 95
LB  - PUB:(DE-HGF)16
C6  - pmid:37924529
DO  - DOI:10.1097/CMR.0000000000000934
UR  - https://inrepo02.dkfz.de/record/285235
ER  -